| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Lycia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $277.05M | Series D | 6/10/2026 | $75M | $388.52M | $2.04 | Janus Henderson Investors, Balyasny Asset Management, Adage Capital Management, HBM Healthcare Investments, OrbiMed, Eli Lilly and Company, Franklin Templeton, Invus, RTW Investments, Venrock | ||||
 | Neomorph | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $208.74M | Series B | 4/13/2026 | $114.04M | $340.23M | $1.32 | Deerfield Management, Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital | ||||
 | Phil | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $119.43M | Series D | 7/3/2021 | $61.34M | $321.12M | $4.06 | Warburg Pincus | ||||
 | Quanta Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $168.34M | Series D | 6/24/2026 | $76.19M | $253.34M | $1.44 | Avidity Partners, Sofinnova Investments, Vida Ventures, Surveyor Capital, Longitude Capital, BVF Partners, AbbVie Ventures, GC&H Investments, WS Investment Company | ||||
 | Scribe Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $120.71M | Series B | 3/31/2021 | $100M | $351.77M | $35.83 | Avoro Ventures, Avoro Capital Advisors, OrbiMed, Andreessen Horowitz, Perceptive Advisors, T. Rowe Price, Wellington Management, RA Capital Management, Menlo Venture | ||||
 | SetPoint Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $303.01M | Series D | 8/11/2025 | $115M | $471.62M | $1.51 | Elevage Medical Technologies, Ally Bridge Group, Northwell Health, SPRIG Equity, Norwest Venture Partners, New Enterprise Associates, Viking Global Investors, Action Potential Venture Capital, Abbott, Boston Scientific, Euclidean Capital, Richard King Mellon Foundation, Morgenthaler Ventures, ShangBay Capital, Ascendum Capital, Catalio Capital Management, Gilmartin Capital, Midas Capital | ||||
 | Vida Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $211.08M | Series F | 6/23/2025 | $35M | $171.6M | $0.92 | Undisclosed Investors | ||||
 | Zephyr AI | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $129.71M | Series A | 3/13/2024 | $69.01M | $482.26M | $17.34 | Revolution Growth, Eli Lilly and Company, Jeff Skoll, EPIQ Capital Group | ||||
 | Arbor Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $331.59M | Series C-2 | 10/8/2025 | $26.09M | $282.07M | $4.52 | Undisclosed Investors | ||||
 | Covera Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $180.66M | Series C-3 | 4/10/2026 | $27.35M | $179.98M | $1.74 | Undisclosed Investors | ||||
 | Entrada Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $204.63M | Series B | 3/31/2021 | $116.25M | $360.98M | $15.72 | Wellington Management, Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment Authority, Moore Strategic Ventures, Goldman Sachs, CureDuchenne Ventures, 5AM Ventures, MPM Capital, Roche Venture Fund, MSD, Agent Capital | ||||
 | Firefly Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $240.86M | Series C | 10/25/2024 | $60M | $348.01M | $6.26 | Undisclosed Investors | ||||
 | Pelago | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $478.23M | Series C | 3/28/2024 | $58M | $349.85M | $17.55 | Atomico, Kinnevik AB, Octopus Ventures, Y Combinator, Eight Roads, GreyMatter Capital | ||||
 | SmarterDx | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $70.97M | Series B | 5/14/2024 | $50M | $341.85M | $16.75 | Transformation Capital, Bessemer Venture Partners, Flare Capital Partners, Floodgate | ||||
 | Capstan Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $152.91M | Series C | 12/11/2024 | $110M | $355.75M | $14.43 | Eclipse, Intuitive Ventures, Yu Galaxy, Gideon Strategic Partners | ||||
 | Detect | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $77.02M | Series A-1 | 7/29/2026 | $31.99M | $118.22M | $1.22 | Undisclosed Investors | ||||
 | Evozyne | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.19M | Series B | 9/27/2023 | $50M | $288.32M | $15.49 | Fidelity Management & Research Company, OrbiMed, NVentures, Paragon Biosciences, Valor Equity Partners | ||||
 | Genalyte | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $30.23M | Series 1 | 1/30/2026 | $30.23M | $58.16M | $0.38 | Undisclosed Investors | ||||
 | Hazel Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $364.29M | Series E | 6/9/2026 | $99.03M | $396.96M | $2.40 | Undisclosed Investors | ||||
 | Ionetix | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $98.68M | Series F | 8/7/2024 | $62.72M | $266.93M | $1.40 | Eli Lilly, POINT Biopharma Global | ||||
 | Luna | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $155.17M | Series C-1 | 6/30/2026 | $59.16M | $144.21M | $0.41 | Undisclosed Investors | ||||
 | Nuna | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $117.69M | Series B-1 | 3/12/2020 | $26.74M | $492.55M | $34.05 | Undisclosed Investors | ||||
 | Qventus | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $155.63M | Series D-1 | 1/13/2025 | $35.81M | $400.12M | $7.95 | KKR, Bessemer Venture Partners, Northwestern Medicine, HonorHealth, Allina Health | ||||
 | Virtual Incision | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $122.22M | Series A-1 | 5/1/2026 | $45.63M | $124.72M | $1.00 | Undisclosed Investors | ||||